Study: NCT00328614

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Samarium-153
Description: Samarium-153 will be administered as a single dose after one month of hormonal therapy. The dose level of Samarium-153 may change to determine maximum tolerated dose (MTD).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Samarium-153
Description: Samarium-153 will be administered as a single dose after one month of hormonal therapy. The dose level of Samarium-153 may change to determine maximum tolerated dose (MTD).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Samarium-153
Description: Samarium-153 will be administered as a single dose after one month of hormonal therapy. The dose level of Samarium-153 may change to determine maximum tolerated dose (MTD).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Samarium-153
Description: Samarium-153 will be administered as a single dose after one month of hormonal therapy. The dose level of Samarium-153 may change to determine maximum tolerated dose (MTD).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Samarium-153
Description: Samarium-153 will be administered as a single dose after one month of hormonal therapy. The dose level of Samarium-153 may change to determine maximum tolerated dose (MTD).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Samarium-153
Description: Samarium-153 will be administered as a single dose after one month of hormonal therapy. The dose level of Samarium-153 may change to determine maximum tolerated dose (MTD).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Total Androgen Suppression (TAS) with Bicalutamide
Description: Patients will receive 5 months of total androgen suppression (TAS) consisting of Zoladex and Casodex. Total androgen suppression will begin 3 months prior to initiation of irradiation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Total Androgen Suppression (TAS) with Bicalutamide
Description: Patients will receive 5 months of total androgen suppression (TAS) consisting of Zoladex and Casodex. Total androgen suppression will begin 3 months prior to initiation of irradiation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Total Androgen Suppression (TAS) with Bicalutamide
Description: Patients will receive 5 months of total androgen suppression (TAS) consisting of Zoladex and Casodex. Total androgen suppression will begin 3 months prior to initiation of irradiation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Total Androgen Suppression (TAS) with Bicalutamide
Description: Patients will receive 5 months of total androgen suppression (TAS) consisting of Zoladex and Casodex. Total androgen suppression will begin 3 months prior to initiation of irradiation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Total Androgen Suppression (TAS) with Bicalutamide
Description: Patients will receive 5 months of total androgen suppression (TAS) consisting of Zoladex and Casodex. Total androgen suppression will begin 3 months prior to initiation of irradiation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Total Androgen Suppression (TAS) with Bicalutamide
Description: Patients will receive 5 months of total androgen suppression (TAS) consisting of Zoladex and Casodex. Total androgen suppression will begin 3 months prior to initiation of irradiation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Total androgen suppression (TAS) with Goserelin Acetate
Description: Patients will receive 5 months of total androgen suppression (TAS) consisting of Zoladex and Casodex. Total androgen suppression will begin 3 months prior to initiation of irradiation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Total androgen suppression (TAS) with Goserelin Acetate
Description: Patients will receive 5 months of total androgen suppression (TAS) consisting of Zoladex and Casodex. Total androgen suppression will begin 3 months prior to initiation of irradiation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Total androgen suppression (TAS) with Goserelin Acetate
Description: Patients will receive 5 months of total androgen suppression (TAS) consisting of Zoladex and Casodex. Total androgen suppression will begin 3 months prior to initiation of irradiation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Total androgen suppression (TAS) with Goserelin Acetate
Description: Patients will receive 5 months of total androgen suppression (TAS) consisting of Zoladex and Casodex. Total androgen suppression will begin 3 months prior to initiation of irradiation.